Table 1.
Baseline demographics and time to cancer occurrence for the anti-TIF1-Ab-positive and negative cohorts
| Total cohort (n = 263) | Anti-TIF1-Ab positive (n = 55) | Anti-TIF1-Ab negative (n = 208) | ||
|---|---|---|---|---|
| Female, n (%) | 181 (69) | 44 (80) | 137 (66)* | |
| Smokers, n (%) | 82 (31) | 17 (31) | 65 (31) | |
| Follow-up, years, median (IQR) | 10 (7–17) | 10 (6–15) | 12 (8–18) | |
| Age of DM onset, years, median (IQR) | No subsequent cancer diagnosis | 47 (35–60) | 45 (34–58) | 47 (37–59) |
| Subsequent cancer diagnosis | 59 (48–66) | 59 (50–65) | 58 (49–69) | |
| Age at cancer diagnosis, years, median (IQR) | 61 (52–68) | 60 (52–67) | 62 (52–70) | |
| Time from DM to cancer onset, years, median (IQR) | 4.3 (1.5–9.4) | 1.4 (0.7–2.5) | 5.0 (2.5–10.4)* | |
| Cancer cases during total follow-up period, n (%) | 53 (20) | 21 (38) | 32 (15)* | |
| Cases classified as CAMa, n (%) | 42 (16) | 21 (38) | 21 (10)* | |
| Patients with cancer within 3 years preceding DM onset, n (%) | 16 (6) | 7 (13) | 9 (4)* | |
| Patients with cancer within 3 years following DM onset, n (%) | 26 (10) | 14 (26) | 12 (6)* |
aCAM: cancer occurring within 3 years either side of DM onset.
Variables of the anti-TIF1-Ab-positive cohort were compared against those of the anti-TIF1-Ab-negative cohort. *P < 0.01 (categorical variables were compared with the chi-squared test, continuous variables were compared using the Mann–Whitney U test). Anti-TIF1-Ab: anti-transcriptional intermediary factor 1 antibody.